HealthDay - TUESDAY, Sept. 6 (HealthDay News) -- Breast cancer patients with the BRCA1 gene mutation have a much better response to neoadjuvant chemotherapy -- chemo given before other treatment -- than other breast cancer patients, a new study finds.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.